Pancreatic cancer gene therapy: From molecular targets to delivery systems

Cancers

Volumn 3, Issue 1, 2011, Pages 368-395

  Fillat, Cristina ^a   Jose, Anabel ^a   Ros, Xavier Bofill De ^a   Mato Berciano, Ana ^a   Maliandi, Maria Victoria ^a   Sobrevals, Luciano ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Clinical trials; Gene delivery routes; Oncolysis; Viral and non viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; HERPESVIRUS VECTOR; IFOSFAMIDE; INTERFERON; INTERLEUKIN 12; LENTIVIRUS VECTOR; LIPOSOME; MICRORNA; MICRORNA 10; MICRORNA 155; NAKED DNA; PARVOVIRUS VECTOR; POLIETHILENIMINE; POLYMER; PROTEIN BAX; PROTEIN TYROSINE KINASE; RECOMBINANT SIMIAN VIRUS 40 VECTOR; RETROVIRUS VECTOR; REXIN G; THROMBOSPONDIN 1; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VECTOR; VIRUS VECTOR; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; DENDRITIC CELL; DNA MODIFICATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; MESENCHYMAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS TUMOR; PROMOTER REGION; PSEUDOTYPING; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ENTRY; VIRUS REPLICATION;

EID: 79953703148     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010368     Document Type: Review

References (154)

1. Ocker, M.; Neureiter, D.; Lueders, M.; Zopf, S.; Ganslmayer, M.; Hahn, E.G.; Herold, C.; Schuppan, D. Variants of bcl-2 specific sirna for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005, 54, 1298-1308.
2. Lopes, R.; Gangeswaran, R.; McNeish, I.; Wang, Y.; Lemoine, N. Expression of the iap protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int. J. Cancer 2007, 120, 2344-2352.
3. Vogler, M.; Durr, K.; Jovanovic, M.; Debatin, K.; Fulda, S. Regulation of trailinduced apoptosis by xiap in pancreatic carcinoma cells. Oncogene 2007, 26, 248-257.
4. Sato, F.; Nagata, C.; Liu, Y.; Suzuki, T.; Kondo, J.; Morohashi, S.; Imaizumi, T.; Kato, Y.; Kijima, H. Period1 is an anti-apoptotic factor in human pancreatic and hepatic cancer cells. J. Biochem. 2009, 146, 833-838.
5. Wack, S.; Rejiba, S.; Parmentier, C.; Aprahamian, M.; Hajri, A. Telomerase transcriptional targeting of inducible bax/trail gene therapy improves gemcitabine treatment of pancreatic cancer. Mol. Ther. 2008, 16, 252-260.
6. Bardeesy, N.; Andrew J. Aguirrea; Gerald C. Chua; Kuang-hung Cheng, L.V.L.; Hezel, A.F.; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S. Redston; Lynda Chin; DePinho, R.A. Both p16ink4a and the p19arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 2006, 103, 5947-5952.
7. Calbó, J.; Marotta, M.; Cascalló, M.; Roig, J.; Gelpí, J.; Fueyo, J.; Mazo, A. Adenovirusmediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther. 2001, 8, 740-750.
8. Cascalló, M.; Mercadé, E.; Capellà, G.; Lluís, F.; Fillat, C.; Gómez-Foix, A.; Mazo, A. Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther. 1999, 6, 428-436.
9. Stoll, V.; Calleja, V.; Vassaux, G.; Downward, J.; Lemoine, N.R. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut 2005, 54, 109-116.
10. Abate-Daga, D.; Garcia-Rodríguez, L.; Sumoy, L.; Fillat, C. Cell cycle control pathways act as conditioning factors for tk/gcv sensitivity in pancreatic cancer cells. Biochim. Biophys. Acta 2010, 1803, 1175-1185.
11. Fillat, C.; Carrio, M.; Cascante, A.; Sangro, B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: Fifteen years of application. Curr. Gene Ther. 2003, 3, 13-26.
12. Garcia-Rodríguez, L.; Abate-Daga, D.; Rojas, A.; González, J.; Fillat, C. E-cadherin contributes to the bystander effect of tk/gcv suicide therapy and enhances its antitumoral activity in pancreatic cancer models. Gene Ther. 2011, 18, 73-81.
13. Carrio, M.; Romagosa, A.; Mercade, E.; Mazo, A.; Nadal, M.; Gomez-Foix, A.M.; Fillat, C. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther. 1999, 6, 547-553.
14. Cascante, A.; Huch, M.; Rodriguez, L.G.; Gonzalez, J.R.; Costantini, L.; Fillat, C. Tat8-tk/gcv suicide gene therapy induces pancreatic tumor regression in vivo. Hum. Gene Ther. 2005, 16, 1377-1388.
15. Evoy, D.; Hirschowitz, E.; Naama, H. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J. Surg. Res. 1997, 69, 226-231.
16. Kanyama, H.; Tomita, N.; Yamono, T. Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of japan-liposome method for cytosine deaminase suicide gene thearpy. Cancer Res. 2001, 61, 14-18.
17. Boucher, P.; Im, M.; Freytag, S. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006, 66, 3230-3237.
18. Secrist, J.A.; Parker, W.B.; Allan, P.W.; Bennett, L.L.; Waud, W.R.; Truss, J.W.; Fowler, A.T.; Montgomery, J.A.; Ealick, S.E.; Wells, A.H.; Gillespie, G.Y.; Gadi, V.K.; Sorscher, E.J. Gene therapy of cancer: Activation of nucleoside prodrugs with E. Coli purine nucleoside phosphorylase. Nucleos. Nucleot. 1999, 18, 745-757.
19. Deharvengt, S.; Wack, S.; Uhring, M.; Aprahamian, M.; Hajri, A. Suicide gene/prodrug therapy for pancreatic adenocarcinoma bye. Coli purine nucleoside phosphorylase and 6-methylpurine 2-deoxyriboside. Pancreas 2004, 28, e54-e64.
20. Lohr, M.; Hoffmeyer, A.; Kroger, J. Microencapsulated cellmediated treatment of inoperable pancreatic carcinoma. Lancet 2001, 357, 1591-1592.
21. Lohr, M.; Hummel, F.; Faulmann, G.; Ringel, J.; Saller, R.; Hain, J.; Gunzburg, W.H.; Salmons, B. Microencapsulated, cyp2b1-transfected cells activating ifosfamide at the site of the tumor: The magic bullets of the 21st century. Cancer Chem other. Pharmacol. 2002, 49 (Suppl. 1), S21-S24.
22. Huch, M.; Abate-Daga, D.; Roig, J.M.; Gonzalez, J.R.; Fabregat, J.; Sosnowski, B.; Mazo, A.; Fillat, C. Targeting the cyp2b 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models. Hum. Gene Ther. 2006, 17, 1187-1200.
23. Carrio, M.; Visa, J.; Cascante, A.; Estivill, X.; Fillat, C. Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome p450 2b 1 in a pancreatic tumor model. Combination with the hsvtk/gcv system. J. Gene Med. 2002, 4, 141-149.
24. Bhat, R.; Dempe, S.; Dinsart, C.; Rommelaere, J. Enhancement of nk cell antitumor responses using an oncolytic parvovirus. Int J. Cancer 2011, 128, 908-919.
25. Mazzolini, G.; Alfaro, C.; Sangro, B.; Feijoo, E.; Ruiz, J.; Benito, A.; Tirapu, I.; Arina, A.; Sola, J.; Herraiz, M.; Lucena, F.; Olague, C.; Subtil, J.; Quiroga, J.; Herrero, I.; Sadaba, B.; Bendandi, M.; Qian, C.; Prieto, J.; Melero, I. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol. 2005, 23, 999-1010.
26. Meng, Y.; Mauceri, H.; Khodarev, N.; Darga, T.; Pitroda, S.; Beckett, M.; Kufe, D.; Weichselbaum, R. Ad. Egr-tnf and local ionizing radiation suppress metastases by interferon-betadependent activation of antigen-specific cd8+ t cells. Mol. Ther. 2010, 18, 912-920.
27. Motoi, F.; Sunamura, M.; Ding, L.; Duda, D.; Yoshida, Y.; Zhang, W.; Matsuno, S.; Hamada, H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum. Gene Ther. 2000, 11, 223-235.
28. MacKenzie, M.J. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol. 2004, 5, 541-549.
29. Sarkar, D.; Su, Z.; Vozhilla, N.; Park, E.; Randolph, A.; Valerie, K.; Fisher, P. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res. 2005, 65, 9056-9063.
30. Ferrantini, M.; Capone, I.; Belardelli, F. Interferon-a and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 2007, 89, 884-893.
31. Gresser, I. The antitumor effects of interferon: A personal history. Biochimie 2007, 89, 723-728.
32. Hance, K.; Rogers, C.; Zaharoff, D.; Canter, D.; Schlom, J.; Greiner, J. The antitumor and immunoadjuvant effects of ifn-alpha in combination with recombinant poxvirus vaccines. Clin. Cancer Res. 2009 15, 2387-2396.
33. Ravet, E.; Lulka, H.; Gross, F.; Casteilla, L.; Buscail, L.; Cordelier, P. Using lentiviral vectors for efficient pancreatic cancer gene therapy. Cancer Gene Ther. 2010, 17, 315-324.
34. Carthew, R.W.; Sontheimer, E.J. Origins and mechanisms of mirnas and sirnas. Cell 2009, 136, 642-655.
35. Lee, E.J.; Gusev, Y.; Jiang, J.; Nuovo, G.J.; Lerner, M.R.; Frankel, W.L.; Morgan, D.L.; Postier, R.G.; Brackett, D.J.; Schmittgen, T.D. Expression profiling identifies microrna signature in pancreatic cancer. Int. J. Cancer 2007, 120, 1046-1054.
36. Roldo, C.; Missiaglia, E.; Hagan, J.P.; Falconi, M.; Capelli, P.; Bersani, S.; Calin, G.A.; Volinia, S.; Liu, C.G.; Scarpa, A.; Croce, C.M. Microrna expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24, 4677-4684.
37. Szafranska, A.E.; Davison, T.S.; John, J.; Cannon, T.; Sipos, B.; Maghnouj, A.; Labourier, E.; Hahn, S.A. Microrna expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26, 4442-4452.
38. Iorio, M.V.; Croce, C.M. Micrornas in cancer: Small molecules with a huge impact. J. Clin. Oncol. 2009, 27, 5848-5856.
39. Giovannetti, E.; Funel, N.; Peters, G.J.; Del Chiaro, M.; Erozenci, L.A.; Vasile, E.; Leon, L.G.; Pollina, L.E.; Groen, A.; Falcone, A.; Danesi, R.; Campani, D.; Verheul, H.M.; Boggi, U. Microrna-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70, 4528-4538.
40. Ali, S.; Ahmad, A.; Banerjee, S.; Padhye, S.; Dominiak, K.; Schaffert, J.M.; Wang, Z.; Philip, P.A.; Sarkar, F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of mir-200 and mir-21 expression by curcumin or its analogue cdf. Cancer Res. 2010, 70, 3606-3617.
41. du Rieu, M.C.; Torrisani, J.; Selves, J.; Al Saati, T.; Souque, A.; Dufresne, M.; Tsongalis, G.J.; Suriawinata, A.A.; Carrere, N.; Buscail, L.; Cordelier, P. Microrna-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin. Chem 2010, 56, 603-612.
42. Weiss, F.U.; Marques, I.J.; Woltering, J.M.; Vlecken, D.H.; Aghdassi, A.; Partecke, L.I.; Heidecke, C.D.; Lerch, M.M.; Bagowski, C.P. Retinoic acid receptor antagonists inhibit mir-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 2009, 137, 2136-2145, e2131-e2137.
43. Greither, T.; Grochola, L.F.; Udelnow, A.; Lautenschlager, C.; Wurl, P.; Taubert, H. Elevated expression of micrornas 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 2010, 126, 73-80.
44. Gironella, M.; Seux, M.; Xie, M.J.; Cano, C.; Tomasini, R.; Gommeaux, J.; Garcia, S.; Nowak, J.; Yeung, M.L.; Jeang, K.T.; Chaix, A.; Fazli, L.; Motoo, Y.; Wang, Q.; Rocchi, P.; Russo, A.; Gleave, M.; Dagorn, J.C.; Iovanna, J.L.; Carrier, A.; Pebusque, M.J.; Dusetti, N.J. Tumor protein 53-induced nuclear protein 1 expression is repressed by mir-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. USA 2007, 104, 16170-16175.
45. Volpers, C.; Kochanek, S. Adenoviral vectors for gene transfer and therapy. J. Gene Med. 2004, 6 (Suppl. 1), S164-S171.
46. Xie, Y.F.; Sheng, W.; Xiang, J.; Zhang, H.; Ye, Z.; Yang, J. Adenovirus-mediated ing4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother. Radiopharm. 2009, 24, 261-269.
47. Pan, X.T.; Zhu, Q.Y.; Li, D.C.; Yang, J.C.; Zhang, Z.X.; Zhu, X.G.; Zhao, H. Effect of recombinant adenovirus vector mediated human interleukin-24 gene transfection on pancreatic carcinoma growth. Chin. Med. J. (Engl.) 2008, 121, 2031-2036.
48. Block, A.; Chen, S.H.; Kosai, K.; Finegold, M.; Woo, S.L. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 1997, 15, 25-34.
49. Hwang, R.; Gordon, E.; Anderson, W.; Parekh, D. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998, 124, 143-150.
50. Green, N.K.; Youngs, D.J.; Neoptolemos, J.P.; Friedlos, F.; Knox, R.J.; Springer, C.J.; Anlezark, G.M.; Michael, N.P.; Melton, R.G.; Ford, M.J.; Young, L.S.; Kerr, D.J.; Searle, P.F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (cb 1954) by retroviral transduction and expression of the e. Coli nitroreductase gene. Cancer Gene Ther. 1997, 4, 229-238.
51. Howard, B.D.; Boenicke, L.; Schniewind, B.; Henne-Bruns, D.; Kalthoff, H. Transduction of human pancreatic tumor cells with vesicular stomatitis virus g-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther. 2000, 7, 927-938.
52. Gordon, E.M.; Liu, P.X.; Chen, Z.H.; Liu, L.; Whitley, M.D.; Gee, C.; Groshen, S.; Hinton, D.R.; Beart, R.W.; Hall, F.L. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin g1 construct. Cancer Res. 2000, 60, 3343-3347.
53. Wanisch, K.; Yanez-Munoz, R.J. Integration-deficient lentiviral vectors: A slow coming of age. Mol. Ther. 2009, 17, 1316-1332.
54. Wang, F.; Chen, L.; Mao, Z.B.; Shao, J.G.; Tan, C.; Huang, W.D. Lentivirus-mediated short hairpin rna targeting the april gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol. Rep. 2008, 20, 135-139.
55. Wang, J.; Shi, Y.Q.; Yi, J.; Ye, S.; Wang, L.M.; Xu, Y.P.; He, M.; Kong, X.M. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with rna interference. J. Dig. Dis. 2008, 9, 228-237.
56. Deharvengt, S.J.; Gunn, J.R.; Pickett, S.B.; Korc, M. Intratumoral delivery of shrna targeting cyclin d1 attenuates pancreatic cancer growth. Cancer Gene Ther. 2009, 17, 325-333.
57. Teschendorf, C.; Emons, B.; Muzyczka, N.; Graeven, U.; Schmiegel, W. Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells. Anticancer Res. 2010, 30, 1931-1935.
58. Noro, T.; Miyake, K.; Suzuki-Miyake, N.; Igarashi, T.; Uchida, E.; Misawa, T.; Yamazaki, Y.; Shimada, T. Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res. 2004, 64, 7486-7490.
59. Dumon, K.R.; Ishii, H.; Vecchione, A.; Trapasso, F.; Baldassarre, G.; Chakrani, F.; Druck, T.; Rosato, E.F.; Williams, N.N.; Baffa, R.; During, M.J.; Huebner, K.; Croce, C.M. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 2001, 61, 4827-4836.
60. Manservigi, R.; Argnani, R.; Marconi, P. Hsv recombinant vectors for gene therapy. Open Virol. J. 2010, 4, 123-156.
61. Reinblatt, M.; Pin, R.H.; Bowers, W.J.; Federoff, H.J.; Fong, Y. Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sflk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann Surg. Oncol. 2005, 12, 1025-1036.
62. McCart, J.A.; Ward, J.M.; Lee, J.; Hu, Y.; Alexander, H.R.; Libutti, S.K.; Moss, B.; Bartlett, D.L. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001, 61, 8751-8757.
63. Puhlmann, M.; Brown, C.K.; Gnant, M.; Huang, J.; Libutti, S.K.; Alexander, H.R.; Bartlett, D.L. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinasedeleted mutant. Cancer Gene Ther. 2000, 7, 66-73.
64. Peplinski, G.R.; Tsung, A.K.; Casey, M.J.; Meko, J.B.; Fredrickson, T.N.; Buller, R.M.; Norton, J.A. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta. Cancer J. Sci. Am. 1996, 2, 21-27.
65. Cordelier, P.; Bienvenu, C.; Lulka, H.; Marrache, F.; Bouisson, M.; Openheim, A.; Strayer, D.S.; Vaysse, N.; Pradayrol, L.; Buscail, L. Replication-deficient rsv40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Ther. 2007, 14, 19-29.
66. Atkinson, H.; Chalmers, R. Delivering the goods: Viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences. Genetica 2010, 138, 485-498.
67. Morille, M.; Passirani, C.; Vonarbourg, A.; Clavreul, A.; Benoit, J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29, 3477-3496.
68. Miyata, K.; Oba, M.; Kano, M.R.; Fukushima, S.; Vachutinsky, Y.; Han, M.; Koyama, H.; Miyazono, K.; Nishiyama, N.; Kataoka, K. Polyplex micelles from triblock copolymers composed of tandemly aligned segments with biocompatible, endosomal escaping, and DNA-condensing functions for systemic gene delivery to pancreatic tumor tissue. Pharm. Res. 2008, 25, 2924-2936.
69. Niidome, T.; Huang, L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 2002, 9, 1647-1652.
70. Deharvengt, S.; Rejiba, S.; Wack, S.; Aprahamian, M.; Hajri, A. Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int. J. Oncol. 2007, 30, 1397-1406.
71. Lu, Y.; Bai, J.G.; Wang, H.H. Gene therapeutic treatment of pancreatic cancer based on injection of pcdna3.1 /cck plasmid with xenogeneic homologous cholecystokinin. Exp. Oncol. 2006, 28, 136-140.
72. Pirollo, K.F.; Rait, A.; Zhou, Q.; Hwang, S.H.; Dagata, J.A.; Zon, G.; Hogrefe, R.I.; Palchik, G.; Chang, E.H. Materializing the potential of small interfering rna via a tumor-targeting nanodelivery system. Cancer Res. 2007, 67, 2938-2943.
73. Shi, Q.; Nguyen, A.T.; Angell, Y.; Deng, D.; Na, C.R.; Burgess, K.; Roberts, D.D.; Brunicardi, F.C.; Templeton, N.S. A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo. Gene Ther. 2010, 17, 1085-1097.
74. Aoki, K.; Furuhata, S.; Hatanaka, K.; Maeda, M.; Remy, J.S.; Behr, J.P.; Terada, M.; Yoshida, T. Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther. 2001, 8, 508-514.
75. Tang, Z.H.; Qiu, W.H.; Wu, G.S.; Yang, X.P.; Zou, S.Q.; Qiu, F.Z. The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma. World J. Gastroenterol. 2002, 8, 908-912.
76. Pecher, G.; Haring, A.; Kaiser, L.; Thiel, E. Mucin gene (muc1) transfected dendritic cells as vaccine: Results of a phase i/ii clinical trial. Cancer Immunol. Immunother. 2002, 51, 669-673.
77. Peron, J.M.; Bureau, C.; Gourdy, P.; Lulka, H.; Souque, A.; Calippe, B.; Selves, J.; Al Saati, T.; Bernad, J.; Cordelier, P.; Couderc, B.; Pradayrol, L.; Pipy, B.; Buscail, L.; Vinel, J.P. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express il12: A role for peritoneal innate immunity. Gut 2007, 56, 107-114.
78. Beckermann, B.M.; Kallifatidis, G.; Groth, A.; Frommhold, D.; Apel, A.; Mattern, J.; Salnikov, A.V.; Moldenhauer, G.; Wagner, W.; Diehlmann, A.; Saffrich, R.; Schubert, M.; Ho, A.D.; Giese, N.; Buchler, M.W.; Friess, H.; Buchler, P.; Herr, I. Vegf expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 2008, 99, 622-631.
79. Kallifatidis, G.; Beckermann, B.M.; Groth, A.; Schubert, M.; Apel, A.; Khamidjanov, A.; Ryschich, E.; Wenger, T.; Wagner, W.; Diehlmann, A.; Saffrich, R.; Krause, U.; Eckstein, V.; Mattern, J.; Chai, M.; Schutz, G.; Ho, A.D.; Gebhard, M.M.; Buchler, M.W.; Friess, H.; Buchler, P.; Herr, I. Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Ther. 2008, 15, 231-240.
80. Zischek, C.; Niess, H.; Ischenko, I.; Conrad, C.; Huss, R.; Jauch, K.W.; Nelson, P.J.; Bruns, C. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann. Surg. 2009, 250, 747-753.
81. Grisendi, G.; Bussolari, R.; Cafarelli, L.; Petak, I.; Rasini, V.; Veronesi, E.; De Santis, G.; Spano, C.; Tagliazzucchi, M.; Barti-Juhasz, H.; Scarabelli, L.; Bambi, F.; Frassoldati, A.; Rossi, G.; Casali, C.; Morandi, U.; Horwitz, E.M.; Paolucci, P.; Conte, P.; Dominici, M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010, 70, 3718-3729.
82. Kidd, S.; Caldwell, L.; Dietrich, M.; Samudio, I.; Spaeth, E.L.; Watson, K.; Shi, Y.; Abbruzzese, J.; Konopleva, M.; Andreeff, M.; Marini, F.C. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010, 12, 615-625.
83. Mohr, A.; Albarenque, S.M.; Deedigan, L.; Yu, R.; Reidy, M.; Fulda, S.; Zwacka, R.M. Targeting of xiap combined with systemic mesenchymal stem cell-mediated delivery of strail ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010, 28, 2109-2120.
84. Bodempudi, V.; Ohlfest, J.R.; Terai, K.; Zamora, E.A.; Vogel, R.I.; Gupta, K.; Hebbel, R.P.; Dudek, A.Z. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Ther. 2010, 17, 855-863.
85. Martuza, R. Conditionally replicating herpes vectors for cancer therapy. J. Clin. Investig 2000, 105, 841-846.
86. Huch, M.; Gros, A.; Jose, A.; Gonzalez, J.R.; Alemany, R.; Fillat, C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia 2009, 11, 518-528, 514 p following 528.
87. Zhang, Y.A.; Nemunaitis, J.; Samuel, S.K.; Chen, P.; Shen, Y.; Tong, A.W. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering rna. Cancer Res. 2006, 66, 9736-9743.
88. Cascante, A.; Abate-Daga, D.; Garcia-Rodriguez, L.; Gonzalez, J.R.; Alemany, R.; Fillat, C. Gcv modulates the antitumoural efficacy of a replicative adenovirus expressing the tat8-tk as a late gene in a pancreatic tumour model. Gene Ther. 2007, 14, 1471-1480.
89. Freytag, S.O.; Barton, K.N.; Brown, S.L.; Narra, V.; Zhang, Y.; Tyson, D.; Nall, C.; Lu, M.; Ajlouni, M.; Movsas, B.; Kim, J.H. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol. Ther. 2007, 15, 1600-1606.
90. Bortolanza, S.; Bunuales, M.; Otano, I.; Gonzalez-Aseguinolaza, G.; Ortiz-de-Solorzano, C.; Perez, D.; Prieto, J.; Hernandez-Alcoceba, R. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in syrian hamsters. Mol. Ther. 2009, 17, 614-622.
91. Kasuya, H.; Nishiyama, Y.; Nomoto, S.; Hosono, J.; Takeda, S.; Nakao, A. Intraperitoneal delivery of hrr3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J. Surg. Oncol. 1999, 72, 136-141.
92. McAuliffe, P.F.; Jarnagin, W.R.; Johnson, P.; Delman, K.A.; Federoff, H.; Fong, Y. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J. Gastrointest Surg. 2000, 4, 580-588.
93. Fu, X.; Tao, L.; Li, M.; Fisher, W.E.; Zhang, X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res. 2006, 12, 3152-3157.
94. Simpson, G.R.; Han, Z.; Liu, B.; Wang, Y.; Campbell, G.; Coffin, R.S. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res. 2006, 66, 4835-4842.
95. Yu, Y.A.; Galanis, C.; Woo, Y.; Chen, N.; Zhang, Q.; Fong, Y.; Szalay, A.A. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus glv-1h68. Mol. Cancer Ther. 2009, 8, 141-151.
96. Tysome, J.R.; Briat, A.; Alusi, G.; Cao, F.; Gao, D.; Yu, J.; Wang, P.; Yang, S.; Dong, Z.; Wang, S.; Deng, L.; Francis, J.; Timiryasova, T.; Fodor, I.; Lemoine, N.R.; Wang, Y. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 2009, 16, 1223-1233.
97. Penheiter, A.R.; Wegman, T.R.; Classic, K.L.; Dingli, D.; Bender, C.E.; Russell, S.J.; Carlson, S.K. Sodium iodide symporter (nis)-mediated radiovirotherapy for pancreatic cancer. AJR Am. J. Roentgenol. 2010, 195, 341-349.
98. Kelly, K.; Nawrocki, S.; Mita, A.; Coffey, M.; Giles, F.J.; Mita, M. Reovirus-based therapy for cancer. Expert Opin. Biol. Ther. 2009, 9, 817-830.
99. Dempe, S.; Stroh-Dege, A.Y.; Schwarz, E.; Rommelaere, J.; Dinsart, C. Smad4: A predictive marker of pdac cell permissiveness for oncolytic infection with parvovirus h-1pv. Int. J. Cancer 2009, 126, 2914-2927.
100. Venticinque, L.; Meruelo, D. Sindbis viral vector induced apoptosis requires translational inhibition and signaling through mcl-1 and bak. Mol. Cancer 2010, 9, 37.
101. Woo, Y.; Kelly, K.J.; Stanford, M.M.; Galanis, C.; Chun, Y.S.; Fong, Y.; McFadden, G. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann. Surg. Oncol. 2008, 15, 2329-2335.
102. Leitner, S.; Sweeney, K.; Oberg, D.; Davies, D.; Miranda, E.; Lemoine, N.R.; Hallden, G. Oncolytic adenoviral mutants with e 1b 19k gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin. Cancer Res. 2009, 15, 1730-1740.
103. Nelson, A.R.; Davydova, J.; Curiel, D.T.; Yamamoto, M. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci. 2009, 100, 2181-2187.
104. Oberg, D.; Yanover, E.; Adam, V.; Sweeney, K.; Costas, C.; Lemoine, N.R.; Hallden, G. Improved potency and selectivity of an oncolytic e1acr2 and e1b19k deleted adenoviral mutant in prostate and pancreatic cancers. Clin. Cancer Res. 2010, 16, 541-553.
105. Kuhlmann, K.F.; Gouma, D.J.; Wesseling, J.G. Adenoviral gene therapy for pancreatic cancer: Where do we stand? Dig. Surg. 2008, 25, 278-292.
106. Li, M.; Rodriguez, J.A.; Fisher, W.E.; Zhang, X.; Chen, C.; Yao, Q. Viral vectors in pancreatic cancer gene therapy. Gene Ther. Mol. Biol. Vol. 2006, 10, 61-70.
107. Jacob, D.; Davis, J.J.; Zhang, L.; Zhu, H.; Teraishi, F.; Fang, B. Suppression of pancreatic tumor growth in the liver by systemic administration of the trail gene driven by the htert promoter. Cancer Gene Ther. 2005, 12, 109-115.
108. Wesseling, J.G.; Bosma, P.J.; Krasnykh, V.; Kashentseva, E.A.; Blackwell, J.L.; Reynolds, P.N.; Li, H.; Parameshwar, M.; Vickers, S.M.; Jaffee, E.M.; Huibregtse, K.; Curiel, D.T.; Dmitriev, I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 2001, 8, 969-976.
109. Nishimoto, T.; Yoshida, K.; Miura, Y.; Kobayashi, A.; Hara, H.; Ohnami, S.; Kurisu, K.; Yoshida, T.; Aoki, K. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Gene Ther. 2009, 16, 669-680.
110. Van Geer, M.A.; Brevoord, D.; Kuhlmann, K.F.; Bakker, C.T.; Mizuguchi, H.; Wesseling, J.G.; Ten Kate, F.J.; Gouma, D.J.; Oude Elferink, R.P.; Bosma, P.J. A fiber modified adenovirus vector that targets to the ephrina2 receptor reveals enhanced gene transfer to ex vivo pancreatic cancer. Int. J. Oncol. 2010, 36, 233-244.
111. Waddington, S.N.; McVey, J.H.; Bhella, D.; Parker, A.L.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S.M.; Greig, J.A.; Denby, L.; Custers, J.; Morita, T.; Francischetti, I.M.; Monteiro, R.Q.; Barouch, D.H.; van Rooijen, N.; Napoli, C.; Havenga, M.J.; Nicklin, S.A.; Baker, A.H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132, 397-409.
112. Kalyuzhniy, O.; Di Paolo, N.C.; Silvestry, M.; Hofherr, S.E.; Barry, M.A.; Stewart, P.L.; Shayakhmetov, D.M. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 2008, 105, 5483-5488.
113. Vigant, F.; Descamps, D.; Jullienne, B.; Esselin, S.; Connault, E.; Opolon, P.; Tordjmann, T.; Vigne, E.; Perricaudet, M.; Benihoud, K. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 2008, 16, 1474-1480.
114. Shayakhmetov, D.M.; Gaggar, A.; Ni, S.; Li, Z.Y.; Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005, 79, 7478-7491.
115. Chawla, S.P.; Chua, V.S.; Fernandez, L.; Quon, D.; Blackwelder, W.C.; Gordon, E.M.; Hall, F.L. Advanced phase i/ii studies of targeted gene delivery in vivo: Intravenous rexin-g for gemcitabine-resistant metastatic pancreatic cancer. Mol. Ther. 2010, 18, 435-441.
116. Kinoh, H.; Inoue, M.; Komaru, A.; Ueda, Y.; Hasegawa, M.; Yonemitsu, Y. Generation of optimized and urokinase-targeted oncolytic sendai virus vectors applicable for various human malignancies. Gene Ther. 2009, 16, 392-403.
117. Holterman, L.; Vogels, R.; van der Vlugt, R.; Sieuwerts, M.; Grimbergen, J.; Kaspers, J.; Geelen, E.; van der Helm, E.; Lemckert, A.; Gillissen, G.; Verhaagh, S.; Custers, J.; Zuijdgeest, D.; Berkhout, B.; Bakker, M.; Quax, P.; Goudsmit, J.; Havenga, M. Novel replication-incompetent vector derived from adenovirus type 11 (ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with ad5. J. Virol. 2004, 78, 13207-13215.
118. Vogels, R.; Zuijdgeest, D.; van Rijnsoever, R.; Hartkoorn, E.; Damen, I.; de Bethune, M.P.; Kostense, S.; Penders, G.; Helmus, N.; Koudstaal, W.; Cecchini, M.; Wetterwald, A.; Sprangers, M.; Lemckert, A.; Ophorst, O.; Koel, B.; van Meerendonk, M.; Quax, P.; Panitti, L.; Grimbergen, J.; Bout, A.; Goudsmit, J.; Havenga, M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 2003, 77, 8263-8271.
119. Kuhlmann, K.F.; van Geer, M.A.; Bakker, C.T.; Dekker, J.E.; Havenga, M.J.; Elferink, R.P.; Gouma, D.J.; Bosma, P.J.; Wesseling, J.G. Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Ther. 2009, 16, 585-597.
120. Toyoda, E.; Doi, R.; Kami, K.; Mori, T.; Ito, D.; Koizumi, M.; Kida, A.; Nagai, K.; Ito, T.; Masui, T.; Wada, M.; Tagawa, M.; Uemoto, S. Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells. Int. J. Oncol. 2008, 33, 1141-1147.
121. Kleeff, J.; Fukahi, K.; Lopez, M.E.; Friess, H.; Buchler, M.W.; Sosnowski, B.A.; Korc, M. Targeting of suicide gene delivery in pancreatic cancer cells via fgf receptors. Cancer Gene Ther. 2002, 9, 522-532.
122. Hoffmann, D.; Wildner, O. Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment. Mol. Cancer Ther. 2006, 5, 374-381.
123. Onimaru, M.; Ohuchida, K.; Mizumoto, K.; Nagai, E.; Cui, L.; Toma, H.; Takayama, K.; Matsumoto, K.; Hashizume, M.; Tanaka, M. Htert-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci. 2010, 101, 735-742.
124. Ramirez, P.J.; Vickers, S.M.; Ono, H.A.; Davydova, J.; Takayama, K.; Thompson, T.C.; Curiel, D.T.; Bland, K.I.; Yamamoto, M. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am. J. Surg. 2008, 195, 481-490.
125. Toyoda, E.; Doi, R.; Kami, K.; Mori, T.; Ito, D.; Koizumi, M.; Kida, A.; Nagai, K.; Ito, T.; Masui, T.; Wada, M.; Tagawa, M.; Uemoto, S. Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer. J. Exp. Clin. Cancer Res. 2008, 27, 30.
126. Yamamoto, M.; Davydova, J.; Wang, M.; Siegal, G.P.; Krasnykh, V.; Vickers, S.M.; Curiel, D.T. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003, 125, 1203-1218.
127. Liu, S.; Wang, X.P.; Brunicardi, F.C. Enhanced cytotoxicity of riptk gene therapy of pancreatic cancer via pdx-1 co-delivery. J. Surg. Res. 2007, 137, 1-9.
128. Ohashi, M.; Kanai, F.; Tanaka, T.; Lan, K.H.; Shiratori, Y.; Komatsu, Y.; Kawabe, T.; Yoshida, H.; Hamada, H.; Omata, M. In Vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn. J. Cancer Res. 1998, 89, 457-462.
129. Wesseling, J.G.; Yamamoto, M.; Adachi, Y.; Bosma, P.J.; van Wijland, M.; Blackwell, J.L.; Li, H.; Reynolds, P.N.; Dmitriev, I.; Vickers, S.M.; Huibregtse, K.; Curiel, D.T. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 2001, 8, 990-996.
130. Chen, L.; Liu, Q.; Qin, R.; Le, H.; Xia, R.; Li, W.; Kumar, M. Amplification and functional characterization of muc1 promoter and gene-virotherapy via a targeting adenoviral vector expressing hsstr2 gene in muc1-positive panc-1 pancreatic cancer cells in vitro. Int. J. Mol. Med 2005, 15, 617-626.
131. Gao, J.; Li, Z.; Chen, Z.; Shao, J.; Zhang, L.; Xu, G.; Tu, Z.; Gong, Y. Antisense smo under the control of the ptch1 promoter delivered by an adenoviral vector inhibits the growth of human pancreatic cancer. Gene Ther. 2006, 13, 1587-1594.
132. Chan, I.; Lebedeva, I.V.; Su, Z.Z.; Sarkar, D.; Valerie, K.; Fisher, P.B. Progression elevated gene-3 promoter (peg-prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hpnpase(old-35)-mediated growth suppression. J. Cell Physiol. 2008, 215, 401-409.
133. Kasuya, H.; Pawlik, T.M.; Mullen, J.T.; Donahue, J.M.; Nakamura, H.; Chandrasekhar, S.; Kawasaki, H.; Choi, E.; Tanabe, K.K. Selectivity of an oncolytic herpes simplex virus for cells expressing the df3/muc1 antigen. Cancer Res. 2004, 64, 2561-2567.
134. Bischoff, J.; Kirn, D.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J.A.; Sampson-Johannes, A.; Fattaey, A.; McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274, 373-376.
135. O'Shea, C.C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.; Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Shen, Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral rna export, rather than p53 inactivation, determines onyx-015 tumor selectivity. Cancer Cell 2004, 6, 611-623.
136. Hecht, J.R.; Bedford, R.; Abbruzzese, J.L.; Lahoti, S.; Reid, T.R.; Soetikno, R.M.; Kirn, D.H.; Freeman, S.M. A phase i/ii trial of intratumoral endoscopic ultrasound injection of onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 2003, 9, 555-561.
137. Fillat, C.; José, A.; Bofill-De Ros, X.; Mato-Berciano, A.; Maliandi, M.; Abate-Daga, D. Controlling adenoviral replication to induce oncolytic efficacy. Open J. Gene Ther. 2010, 3, 15-23.
138. Kitajewski, J.; Schneider, R.J.; Safer, B.; Munemitsu, S.M.; Samuel, C.E.; Thimmappaya, B.; Shenk, T. Adenovirus vai rna antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eif-2 alpha kinase. Cell 1986, 45, 195-200.
139. Cascallo, M.; Capella, G.; Mazo, A.; Alemany, R. Ras-dependent oncolysis with an adenovirus vai mutant. Cancer Res. 2003, 63, 5544-5550.
140. Mehta, H.; Muller, J.; Markovitz, N.S. Ultrastructural analysis of icp34.5-herpes simplex virus 1 replication in mouse brain cells in vivo. J. Virol. 2010, 84, 10982-10990.
141. Kuppen, P.J.; van der Eb, M.M.; Jonges, L.E.; Hagenaars, M.; Hokland, M.E.; Nannmark, U.; Goldfarb, R.H.; Basse, P.H.; Fleuren, G.J.; Hoeben, R.C.; van de Velde, C.J. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem. Cell Biol. 2001, 115, 67-72.
142. Di Paolo, N.C.; van Rooijen, N.; Shayakhmetov, D.M. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol. Ther. 2009, 17, 675-684.
143. Harvey, B.G.; Hackett, N.R.; El-Sawy, T.; Rosengart, T.K.; Hirschowitz, E.A.; Lieberman, M.D.; Lesser, M.L.; Crystal, R.G. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 1999, 73, 6729-6742.
144. Hoffmann, D.; Wildner, O. Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol. Cancer Ther. 2006, 5, 2013-2022.
145. Mok, W.; Stylianopoulos, T.; Boucher, Y.; Jain, R.K. Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy. Clin. Cancer Res. 2009, 15, 2352-2360.
146. de Vrij, J.; Willemsen, R.A.; Lindholm, L.; Hoeben, R.C.; Bangma, C.H.; Barber, C.; Behr, J.P.; Briggs, S.; Carlisle, R.; Cheng, W.S.; Dautzenberg, I.J.; de Ridder, C.; Dzojic, H.; Erbacher, P.; Essand, M.; Fisher, K.; Frazier, A.; Georgopoulos, L.J.; Jennings, I.; Kochanek, S.; Koppers-Lalic, D.; Kraaij, R.; Kreppel, F.; Magnusson, M.; Maitland, N.; Neuberg, P.; Nugent, R.; Ogris, M.; Remy, J.S.; Scaife, M.; Schenk-Braat, E.; Schooten, E.; Seymour, L.; Slade, M.; Szyjanowicz, P.; Totterman, T.; Uil, T.G.; Ulbrich, K.; van der Weel, L.; van Weerden, W.; Wagner, E.; Zuber, G. Adenovirus-derived vectors for prostate cancer gene therapy. Hum. Gene Ther. 2009, 21, 795-805.
147. Cheng, J.; Sauthoff, H.; Huang, Y.; Kutler, D.I.; Bajwa, S.; Rom, W.N.; Hay, J.G. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol. Ther. 2007, 15, 1982-1990.
148. Chadha, M.K.; Litwin, A.; Levea, C.; Iyer, R.; Yang, G.; Javle, M.; Gibbs, J.F. Surgical resection after tnferade therapy for locally advanced pancreatic cancer. JOP 2009, 10, 535-538.
149. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
150. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea--a paradigm shift. Cancer Res. 2006, 66, 1883-1890, discussion 1895-1886.
151. Visvader, J.E.; Lindeman, G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755-768.
152. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313-323.
153. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030-1037.
154. Mueller, M.T.; Hermann, P.C.; Witthauer, J.; Rubio-Viqueira, B.; Leicht, S.F.; Huber, S.; Ellwart, J.W.; Mustafa, M.; Bartenstein, P.; D'Haese, J.G.; Schoenberg, M.H.; Berger, F.; Jauch, K.W.; Hidalgo, M.; Heeschen, C. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137, 1102-1113.